Fig. 7
From: Nobiletin alleviates atherosclerosis by inhibiting lipid uptake via the PPARG/CD36 pathway
By modulating the PPARG/CD36 signaling pathway, NOB inhibits foam cells formation. An ex vivo model of atherosclerosis was constructed, and the model was deintervened with NOB (10 µM, 50 µM) for 48 h. RAW264.7 Lipid droplet content in cells is tested using Oil Red O staining (at six random locations; 400× magnification) (A, B) (n = 6). The intracellular expression levels of TC and TG were measured by biochemical kits according to the above grouping and interventions (C, D) (n = 3). Different concentrations of NOB were used to treat an ex vivo model of atherosclerosis, and the protein content of CD36 and PPARG was measured by WB (E-G) (n = 3). Inflammatory factors CCL2 and IL-6 in cell supernatants were quantified by ELISA (H, I) (n = 3). **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. the control group; #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 vs. the OxLDL group